A constitutively high concentrations of nuclear beta-catenin was reported in PTEN-null prostate cancer cell lines, and a re-expression of PTEN in those cells resulted in activation of GSK-3β and degradation of beta-catenin [64]. The gene discussed is GSK3B; the disease is prostate carcinoma.